GO
| HSI1 | 25,962.73 | -426.31 | 325.39B |
| HSCEI1 | 8,691.03 | -167.60 | 91.91B |
| Back Zoom + Zoom - Block Traded | |
|
FOSUN PHARMA Granted Exclusive Commercialization Option for Alzheimer's Disease Therapy
2026-05-14 09:16:18 FOSUN PHARMA (02196.HK) announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development (Fosun Pharma Industrial), has been granted an exclusive option by AriBio. Pursuant to the agreement, upon completion of the global multi-center Phase III clinical trial of the licensed product for the treatment of early-stage Alzheimer's disease, AriBio shall provide Fosun Pharma Industrial with all top-line data. Fosun Pharma Industrial has the right to decide whether to exercise the exclusive option no later than 90 calendar days after receipt of such top-line data. If the option is exercised, Fosun Pharma Industrial will obtain from AriBio exclusive rights on a global basis to develop, register, manufacture and commercialize the licensed product within the licensed field and territory, including but not limited to the United States, Europe and Japan, and will act as the marketing authorization holder for the product in those regions. Under the agreement, Fosun is required to pay an option fee of USD60 million. Upon exercise of the option, it will pay an upfront payment of USD80 million and up to USD100 million in regulatory milestone payments, in addition to sales milestones and low double-digit sales royalties. ~ AASTOCKS Financial News Website: www.aastocks.com | |